Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Marie-Paule Lecart & Jean-Yves Reginster. (2011) Current options for the management of postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy 12:16, pages 2533-2552.
Read now
Read now
A.D. Walker & J.D. Adachi. (2011) In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada. Current Medical Research and Opinion 27:9, pages 1749-1754.
Read now
Read now
Michael Pazianas, Cyrus Cooper, F Hal Ebetino & R Graham G Russell. (2010) Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Therapeutics and Clinical Risk Management 6, pages 325-343.
Read now
Read now
Articles from other publishers (12)
Aasis Unnanuntana, Atthakorn Jarusriwanna & Panupan Songcharoen. (2017) Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment. PLOS ONE 12:7, pages e0180325.
Crossref
Crossref
J.Y. Reginster, A. Neuprez, N. Dardenne, C. Beaudart, P. Emonts & O. Bruyere. (2014) Efficacy and safety of currently marketed anti-osteoporosis medications. Best Practice & Research Clinical Endocrinology & Metabolism 28:6, pages 809-834.
Crossref
Crossref
Wojciech P. Olszynski, Jonathan D. Adachi & K. Shawn Davison. (2014)
Differences in
In Vitro
Disintegration Time among Canadian Brand and Generic Bisphosphonates
. Journal of Osteoporosis 2014, pages 1-6.
Crossref
Crossref
Jacques P Brown, Kenneth S Davison, Wojciech P Olszynski, Karen A Beattie & Jonathan D Adachi. (2013) A critical review of brand and generic alendronate for the treatment of osteoporosis. SpringerPlus 2:1.
Crossref
Crossref
Caterina Musolino & Alessandro Allegra. 2013. Pathobiology of Cancer Regimen-Related Toxicities. Pathobiology of Cancer Regimen-Related Toxicities
249
282
.
Claudia Gómez Acotto, Carlos Antonelli, Damien Flynn, Dennis McDaid & Emilio J. A. Roldán. (2012) Upper Gastrointestinal Tract Transit Times of Tablet and Drinkable Solution Formulations of Alendronate: A Bioequivalence and a Quantitative, Randomized Study using Video Deglutition. Calcified Tissue International 91:5, pages 325-334.
Crossref
Crossref
J. A. Kanis, J.-Y. Reginster, J.-M. Kaufman, J.-D. Ringe, J. D. Adachi, M. Hiligsmann, R. Rizzoli & C. Cooper. (2011) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporosis International 23:1, pages 213-221.
Crossref
Crossref
Kurt Lippuner, Richard F. Pollock, Jayne Smith-Palmer, Thomas Meury & William J. Valentine. (2011) A Review of the Cost Effectiveness of Bisphosphonates in the Treatment of Post-Menopausal Osteoporosis in Switzerland. Applied Health Economics and Health Policy 9:6, pages 403-417.
Crossref
Crossref
Lluis Pérez Edo, Alberto Alonso Ruiz, Daniel Roig Vilaseca, Alberto García Vadillo, Nuria Guañabens Gay, Pilar Peris, Antonio Torrijos Eslava, Chesús Beltrán Audera, Jordi Fiter Aresté, Luis Arboleya Rodríguez, Jenaro Graña Gil, Jordi Carbonell Abelló, Joan Miquel Nolla, Susana Holgado Pérez, Esteban Salas Heredia, Jaime Zubieta Tabernero, Javier Del Pino Montes, Josep Blanch i. Rubió, Manuel Caamaño Freire, Manuel Rodríguez Pérez, Santos Castañeda, Dacia Cerdá, Carmen Gómez Vaquero, Javier Calvo Catalá, Manel Ciria & Estíbaliz Loza. (2011) 2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis. Reumatología Clínica (English Edition) 7:6, pages 357-379.
Crossref
Crossref
Lluís Pérez Edo, Alberto Alonso Ruiz, Daniel Roig Vilaseca, Alberto García Vadillo, Nuria Guañabens Gay, Pilar Peris, Antonio Torrijos Eslava, Chesús Beltrán Audera, Jordi Fiter Aresté, Luis Arboleya Rodríguez, Jenaro Graña Gil, Jordi Carbonell Abelló, Joan Miquel Nolla, Susana Holgado Pérez, Esteban Salas Heredia, Jaime Zubieta Tabernero, Javier Del Pino Montes, Josep Blanch i Rubió, Manuel Caamaño Freire, Manuel Rodríguez Pérez, Santos Castañeda, Dacia Cerdá, Carmen Gómez Vaquero, Javier Calvo Catalá, Manel Ciria & Estíbaliz Loza. (2011) Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis. Reumatología Clínica 7:6, pages 357-379.
Crossref
Crossref
Daniel T Grima, Alexandra Papaioannou, Parisa Airia, George Ioannidis & Jonathan D Adachi. (2010) Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. BMC Musculoskeletal Disorders 11:1.
Crossref
Crossref
J.-J. Body, P. Bergmann, S. Boonen, Y. Boutsen, J.-P. Devogelaer, S. Goemaere, J.-M. Kaufman, S. Rozenberg & J.-Y. Reginster. (2010) Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporosis International 21:10, pages 1657-1680.
Crossref
Crossref